Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer ; volume:9 ; number:1 ; day:11 ; month:8 ; year:2023 ; pages:1-9 ; date:12.2023
npj Breast cancer ; 9, Heft 1 (11.8.2023), 1-9, 12.2023
- Urheber
-
Khorrami, Mohammadhadi
Viswanathan, Vidya Sakar
Reddy, Priyanka
Braman, Nathaniel
Kunte, Siddharth
Gupta, Amit
Abraham, Jame
Montero, Alberto J.
Madabhushi, Anant
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-023-00574-7
- URN
-
urn:nbn:de:101:1-2024020512365704756859
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Khorrami, Mohammadhadi
- Viswanathan, Vidya Sakar
- Reddy, Priyanka
- Braman, Nathaniel
- Kunte, Siddharth
- Gupta, Amit
- Abraham, Jame
- Montero, Alberto J.
- Madabhushi, Anant
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
Regulation of CDK4
Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma
Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
Gene expression predicts dormant metastatic breast cancer cell phenotype
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
Regulation of CDK4
Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma
Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
Gene expression predicts dormant metastatic breast cancer cell phenotype
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
Regulation of CDK4
Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma
Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer